[go: up one dir, main page]

EA201790530A1 - Агенты, связывающиеся с cd123, и виды их применения - Google Patents

Агенты, связывающиеся с cd123, и виды их применения

Info

Publication number
EA201790530A1
EA201790530A1 EA201790530A EA201790530A EA201790530A1 EA 201790530 A1 EA201790530 A1 EA 201790530A1 EA 201790530 A EA201790530 A EA 201790530A EA 201790530 A EA201790530 A EA 201790530A EA 201790530 A1 EA201790530 A1 EA 201790530A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
proposed
cancer
antigen binding
binding fragments
Prior art date
Application number
EA201790530A
Other languages
English (en)
Other versions
EA037647B1 (ru
Inventor
Франсуа Годе
Рикардо Аттар
Бенджамин К. Харман
Инчжэ Ли
Цзиньцюань Ло
Ронан Макдейд
Стивен К. Померантц
Сьюзан Х. Тэм
Алексей Тепляков
Джон Уилер
Шэн-Дзюн Ву
Дженнифер Ф. Немет
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201790530A1 publication Critical patent/EA201790530A1/ru
Publication of EA037647B1 publication Critical patent/EA037647B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

В настоящем документе предлагаются антитела, иммуноспецифически связывающиеся с CD123. Также описываются родственные полинуклеотиды, способные кодировать предложенные CD123-специфические антитела или антигенсвязывающие фрагменты, клетки, экспрессирующие предложенные антитела или антигенсвязывающие фрагменты, а также соответствующие векторы и меченные с возможностью обнаружения антитела или антигенсвязывающие фрагменты. Кроме того, описываются способы применения предложенных антител. Например, предложенные антитела можно использовать для диагностики, лечения или контроля прогрессирования, регрессирования или стабильности течения рака с экспрессией CD123; для определения того, следует ли проводить лечение рака у пациента; или для определения того, поражен ли субъект раковым заболеванием с экспрессией CD123 и, следовательно, ответит ли он на лечение CD123-специфическим противораковым препаратом, например мультиспецифическими антителами к CD123 и CD3, описанными в настоящем документе.
EA201790530A 2014-09-05 2015-09-03 Агенты, связывающиеся с cd123, и виды их применения EA037647B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05
PCT/US2015/048316 WO2016036937A1 (en) 2014-09-05 2015-09-03 Cd123 binding agents and uses thereof

Publications (2)

Publication Number Publication Date
EA201790530A1 true EA201790530A1 (ru) 2018-03-30
EA037647B1 EA037647B1 (ru) 2021-04-27

Family

ID=54150667

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790530A EA037647B1 (ru) 2014-09-05 2015-09-03 Агенты, связывающиеся с cd123, и виды их применения

Country Status (39)

Country Link
US (1) US9850310B2 (ru)
EP (2) EP3189081B1 (ru)
JP (2) JP6805130B2 (ru)
KR (1) KR102540192B1 (ru)
CN (1) CN107074956B (ru)
AR (1) AR101765A1 (ru)
AU (1) AU2015311931B2 (ru)
CA (1) CA2959171C (ru)
CL (1) CL2017000515A1 (ru)
CO (1) CO2017002196A2 (ru)
CR (1) CR20170079A (ru)
CY (1) CY1122858T1 (ru)
DK (1) DK3189081T3 (ru)
EA (1) EA037647B1 (ru)
EC (1) ECSP17020812A (ru)
ES (1) ES2791249T3 (ru)
HR (1) HRP20200745T1 (ru)
HU (1) HUE048791T2 (ru)
IL (1) IL250770B (ru)
JO (1) JO3568B1 (ru)
LT (1) LT3189081T (ru)
MA (2) MA40609B1 (ru)
ME (1) ME03724B (ru)
MX (1) MX384424B (ru)
MY (1) MY186337A (ru)
NI (1) NI201700025A (ru)
PE (1) PE20171556A1 (ru)
PH (1) PH12017500472A1 (ru)
PL (1) PL3189081T3 (ru)
PT (1) PT3189081T (ru)
RS (1) RS60305B1 (ru)
SG (1) SG11201701599UA (ru)
SI (1) SI3189081T1 (ru)
SM (1) SMT202000253T1 (ru)
TW (1) TWI693233B (ru)
UA (1) UA120060C2 (ru)
UY (1) UY36289A (ru)
WO (1) WO2016036937A1 (ru)
ZA (1) ZA201702369B (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ701825A (en) * 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN114230668B (zh) 2015-01-23 2025-07-11 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
IL293719B2 (en) 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
JP7203497B2 (ja) 2015-06-29 2023-01-13 イミュノジェン・インコーポレーテッド 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CA3006462C (en) 2015-12-14 2023-10-31 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10544221B2 (en) * 2016-05-20 2020-01-28 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017211731A1 (en) 2016-06-06 2017-12-14 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
CN109310762A (zh) 2016-06-07 2019-02-05 宏观基因有限公司 联合疗法
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
UA127450C2 (uk) * 2016-09-21 2023-08-30 Аптево Рісьорч Енд Дівелопмент Елелсі Рекомбінантний поліпептид, що зв'язується з cd123
AU2017363302A1 (en) 2016-11-23 2019-06-27 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
BR112019010604A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteína de ligação ao antígeno da membrana próstata-específico
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CA3049689A1 (en) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
WO2018156740A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
AU2018265860B2 (en) 2017-05-12 2022-08-11 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
EP3668898B1 (en) 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
RS65978B1 (sr) 2017-10-13 2024-10-31 Harpoon Therapeutics Inc Trispecifični proteini i postupci primene
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
IL274095B2 (en) * 2017-10-27 2025-03-01 Pfizer Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
CN111465618A (zh) 2017-12-12 2020-07-28 宏观基因有限公司 双特异性cd16-结合分子及其在疾病治疗中的用途
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
JP7377590B2 (ja) * 2018-03-14 2023-11-10 ノビミューン エスアー 抗ｃｄ３イプシロン抗体およびそれを使用する方法
CN113164588A (zh) 2018-05-16 2021-07-23 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
CA3101304A1 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and their uses
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CR20200563A (es) 2018-05-24 2021-05-11 Janssen Biotech Inc Agentes aglutinantes de psma y usos de estos
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
KR102306346B1 (ko) * 2018-10-17 2021-09-30 주식회사 굳티셀 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
MX2021010857A (es) * 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
EP3956022A1 (en) 2019-04-19 2022-02-23 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
MX2021013532A (es) * 2019-05-08 2022-02-11 Janssen Biotech Inc Materiales y metodos para modular la inmunidad mediada por celulas t.
CR20210576A (es) 2019-05-21 2021-12-15 Novartis Ag Moléculas de unión a cd19 y usos de las mismas
CN110407924B (zh) * 2019-07-24 2021-12-21 暨南大学 靶向cd133的结合蛋白及其应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
BR112022018176A2 (pt) 2020-03-13 2022-12-06 Janssen Biotech Inc Materiais e métodos para ligação de siglec-3/cd33
BR112022023392A2 (pt) * 2020-05-19 2022-12-20 Janssen Biotech Inc Composições que compreendem um agente terapêutico de redirecionamento de células t e um inibidor da via de adesão de vla-4
CA3199447A1 (en) * 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
CA3206883A1 (en) 2020-12-31 2022-07-07 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
WO2022243838A1 (en) * 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
GB202503987D0 (en) 2021-05-19 2025-04-30 Asher Biotherapeutics Inc Il-21 Polypeptides and targeted constructs
EP4384218A2 (en) * 2021-08-09 2024-06-19 Merck Patent GmbH Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
CN118574646A (zh) * 2022-01-19 2024-08-30 上海优替济生生物医药有限公司 环状rna及其用途
JP2025512377A (ja) 2022-04-11 2025-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ユニバーサルな腫瘍細胞殺傷のための組成物及び方法
TW202413419A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1997024373A1 (en) 1995-12-29 1997-07-10 Medvet Science Pty. Limited Monoclonal antibody antagonists to haemopoietic growth factors
ATE294860T1 (de) 1997-09-16 2005-05-15 Egea Biosciences Llc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
CN102459342B (zh) * 2009-04-27 2015-01-07 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗il-3ra抗体
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011038301A2 (en) * 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
NZ701825A (en) 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
ES2924722T3 (es) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3

Also Published As

Publication number Publication date
EA037647B1 (ru) 2021-04-27
AU2015311931B2 (en) 2020-09-03
MA40609B1 (fr) 2020-05-29
CN107074956A (zh) 2017-08-18
MX2017002891A (es) 2017-10-11
BR112017004322A2 (pt) 2017-12-05
HUE048791T2 (hu) 2020-09-28
TW201625687A (zh) 2016-07-16
NI201700025A (es) 2017-06-22
CA2959171C (en) 2023-11-14
TWI693233B (zh) 2020-05-11
US20160068605A1 (en) 2016-03-10
KR20170049554A (ko) 2017-05-10
SMT202000253T1 (it) 2020-07-08
ECSP17020812A (es) 2018-07-31
WO2016036937A1 (en) 2016-03-10
HRP20200745T1 (hr) 2020-08-07
ME03724B (me) 2021-01-20
JP6805130B2 (ja) 2020-12-23
IL250770A0 (en) 2017-04-30
MX384424B (es) 2025-03-14
CY1122858T1 (el) 2021-05-05
RS60305B1 (sr) 2020-07-31
CL2017000515A1 (es) 2018-03-16
AR101765A1 (es) 2017-01-11
ZA201702369B (en) 2018-12-19
MA53145A (fr) 2021-05-19
JO3568B1 (ar) 2020-07-05
UY36289A (es) 2016-04-01
IL250770B (en) 2020-10-29
PT3189081T (pt) 2020-05-25
KR102540192B1 (ko) 2023-06-02
DK3189081T3 (da) 2020-05-04
JP2021050216A (ja) 2021-04-01
MY186337A (en) 2021-07-13
JP2017529838A (ja) 2017-10-12
AU2015311931A1 (en) 2017-03-16
SI3189081T1 (sl) 2020-07-31
EP3189081B1 (en) 2020-02-19
PH12017500472A1 (en) 2017-07-31
CR20170079A (es) 2017-04-27
UA120060C2 (uk) 2019-09-25
PL3189081T3 (pl) 2020-10-05
US9850310B2 (en) 2017-12-26
SG11201701599UA (en) 2017-03-30
ES2791249T3 (es) 2020-11-03
EP3189081A1 (en) 2017-07-12
EP3722315A1 (en) 2020-10-14
CO2017002196A2 (es) 2017-07-28
CA2959171A1 (en) 2016-03-10
LT3189081T (lt) 2020-05-11
PE20171556A1 (es) 2017-10-27
CN107074956B (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
EA201990346A1 (ru) Антитела к gprc5d, биспецифические антигенсвязывающие молекулы, которые связывают gprc5d и cd3, и их применение
EA201891084A1 (ru) Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
EA201890513A1 (ru) Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201791171A1 (ru) Антитела к tigit
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201692459A1 (ru) Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
RU2757308C2 (ru) Введение сконструированных т-клеток для лечения рака центральной нервной системы
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA201591791A1 (ru) Антитела pac1 человека
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
EA201891998A1 (ru) Антитела к gitr, способы и применение
EA201990927A1 (ru) Антитела против lag-3 и способы их применения
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения